Howard J Worman Selected Research

Lamin Type A (Lamin A)

1/2021	Ryanodine receptor remodeling in cardiomyopathy and muscular dystrophy caused by lamin A/C gene mutation.
12/2019	ERK1/2 Phosphorylation of FHOD Connects Signaling and Nuclear Positioning Alternations in Cardiac Laminopathy.
1/2019	Postnatal development of mice with combined genetic depletions of lamin A/C, emerin and lamina-associated polypeptide 1.
1/2018	Elevated dual specificity protein phosphatase 4 in cardiomyopathy caused by lamin A/C gene mutation is primarily ERK1/2-dependent and its depletion improves cardiac function and survival.
1/2018	Cell signaling abnormalities in cardiomyopathy caused by lamin A/C gene mutations.
1/2018	Cofilin-1 phosphorylation catalyzed by ERK1/2 alters cardiac actin dynamics in dilated cardiomyopathy caused by lamin A/C gene mutation.
1/2017	Extracellular matrix remodeling and transforming growth factor-β signaling abnormalities induced by lamin A/C variants that cause lipodystrophy.
1/2017	Decreased WNT/β-catenin signalling contributes to the pathogenesis of dilated cardiomyopathy caused by mutations in the lamin a/C gene.
1/2017	Macrocyclic MEK1/2 inhibitor with efficacy in a mouse model of cardiomyopathy caused by lamin A/C gene mutation.
1/2016	Targeting Mitogen-Activated Protein Kinase Signaling in Mouse Models of Cardiomyopathy Caused by Lamin A/C Gene Mutations.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Howard J Worman Research Topics

Disease

30	Cardiomyopathies (Cardiomyopathy) 01/2021 - 06/2002
19	Laminopathies 01/2022 - 11/2004
15	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/2021 - 01/2009
13	Muscular Dystrophies (Muscular Dystrophy) 01/2021 - 06/2002
12	Lipodystrophy 01/2017 - 06/2002
11	Progeria (Hutchinson Gilford Syndrome) 01/2022 - 06/2005
10	Emery-Dreifuss Muscular Dystrophy (Scapuloperoneal Muscular Dystrophy) 01/2021 - 01/2003
8	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 10/2012 - 06/2003
6	Autosomal Emery-Dreifuss Muscular Dystrophy 01/2021 - 08/2006
6	Fibrosis (Cirrhosis) 01/2017 - 07/2010
6	Familial Partial Lipodystrophy (Dunnigan Syndrome) 01/2017 - 01/2003
4	Rupture 01/2021 - 01/2014
4	X-Linked Emery-Dreifuss Muscular Dystrophy 12/2015 - 01/2005
4	Muscular Diseases (Myopathy) 01/2015 - 01/2003
4	Premature Aging 06/2012 - 02/2004
3	Heart Failure 01/2017 - 09/2011
3	Left Ventricular Dysfunction 01/2017 - 10/2014
2	Jaundice (Icterus) 10/2021 - 05/2015
2	Inflammation (Inflammations) 01/2016 - 03/2003
2	Autoimmune Diseases (Autoimmune Disease) 10/2012 - 07/2011
2	Peripheral Nervous System Diseases (PNS Diseases) 11/2009 - 01/2005
2	Chronic Hepatitis C 10/2007 - 05/2002
1	Thrombocytopenia (Thrombopenia) 10/2021
1	Hypoxia (Hypoxemia) 10/2021
1	Sepsis (Septicemia) 10/2021
1	Fever (Fevers) 10/2021
1	Leukopenia 10/2021
1	Leukocytosis (Pleocytosis) 10/2021
1	Hypotension (Low Blood Pressure) 10/2021
1	Liver Diseases (Liver Disease) 08/2021
1	Non-alcoholic Fatty Liver Disease 01/2019
1	Atherosclerosis 01/2018
1	Vomiting 05/2015
1	Weight Loss (Weight Reduction) 05/2015
1	Fatigue 05/2015
1	Nausea 05/2015
1	Dyskinesias (Dyskinesia) 05/2015
1	Type 2E Charcot-Marie-Tooth disease 04/2015
1	Genomic Instability 03/2013
1	Chromosome Aberrations (Chromosome Abnormalities) 03/2013
1	High-Frequency Hearing Loss 02/2013

Drug/Important Bio-Agent (IBA)

37	LaminsIBA 01/2021 - 01/2003
35	Lamin Type A (Lamin A)IBA 01/2021 - 06/2002
26	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2002
9	prelamin AIBA 01/2022 - 08/2008
8	Intermediate Filament ProteinsIBA 01/2021 - 02/2004
8	emerinIBA 10/2019 - 04/2003
8	Mitogen-Activated Protein KinasesIBA 01/2016 - 08/2007
6	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2018 - 01/2009
4	Mitogen-Activated Protein Kinase 3IBA 01/2016 - 10/2012
4	AutoantibodiesIBA 10/2012 - 05/2006
4	AntibodiesIBA 10/2012 - 03/2003
3	Amino Acids FDA Link 01/2021 - 06/2007
3	Nuclear Proteins (Protein, Nuclear)IBA 01/2020 - 01/2014
3	Peptides (Polypeptides)IBA 05/2014 - 05/2003
3	Antinuclear AntibodiesIBA 10/2012 - 06/2003
3	JNK Mitogen-Activated Protein KinasesIBA 10/2012 - 07/2010
3	AutoantigensIBA 09/2010 - 06/2003
3	Transaminases (Aminotransferases)IBA 10/2005 - 05/2002
2	BilirubinIBA 10/2021 - 08/2021
2	Phosphotransferases (Kinase)IBA 12/2019 - 01/2016
2	LipidsIBA 01/2019 - 10/2005
2	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2017 - 01/2016
2	AZD 6244IBA 10/2014 - 02/2012
2	Sirolimus (Rapamycin)FDA Link 01/2013 - 07/2012
2	Nuclear Antigens (Extractable Nuclear Antigens)IBA 10/2012 - 12/2010
2	DNA (Deoxyribonucleic Acid)IBA 09/2011 - 05/2003
2	EnzymesIBA 07/2011 - 12/2010
1	CreatinineIBA 10/2021
1	ProcalcitoninIBA 10/2021
1	AlbuminsIBA 08/2021
1	Cofilin 1IBA 01/2021
1	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 01/2021
1	CaspasesIBA 01/2020
1	Protein Isoforms (Isoforms)IBA 12/2019
1	protein phosphatase 4IBA 01/2018
1	Extracellular Matrix ProteinsIBA 01/2017
1	CateninsIBA 01/2017
1	CholesterolIBA 01/2016
1	Connective Tissue Growth FactorIBA 01/2016
1	Bile Acids and Salts (Bile Acids)IBA 01/2016
1	hydroxycutIBA 05/2015
1	neurofilament protein LIBA 04/2015
1	Angiotensin IIIBA 10/2014
1	benazepril (Briem)FDA LinkGeneric 10/2014
1	MAP Kinase Kinase 1IBA 10/2014
1	IsoenzymesIBA 01/2014
1	ANC 1IBA 01/2014
1	Pharmaceutical PreparationsIBA 07/2013
1	CamptothecinIBA 03/2013
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 03/2013
1	Cisplatin (Platino)FDA LinkGeneric 03/2013
1	Dual-Specificity PhosphatasesIBA 11/2012
1	ARRY-371797IBA 10/2012
1	MitogensIBA 10/2012
1	nuclear pore protein p62IBA 10/2012
1	CollagenIBA 10/2012
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 10/2012

Therapy/Procedure

6	Therapeutics 01/2017 - 05/2002
1	Drug Therapy (Chemotherapy) 01/2018